Beurs gesloten -
Hong Kong S.E.
10:08:17 07-05-2024
|
Variatie 5 dagen
|
Verschil t.o.v. 1 jan (%)
|
12,8
HKD
|
+1,11%
|
|
-2,14%
|
+34,88%
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Marktkapitalisatie
1 |
17.593
|
6.540
|
4.374
|
5.052
|
7.590
|
10.393
|
-
|
-
|
Bedrijfswaarde
1 |
17.849
|
5.031
|
6.436
|
7.873
|
7.590
|
10.393
|
10.393
|
10.393
|
K/w-verhouding
|
9,86
x
|
14
x
|
-7,42
x
|
63,8
x
|
3,82
x
|
-
|
-
|
-
|
Dividendrendement
|
3,29%
|
1,35%
|
-
|
-
|
-
|
8,47%
|
8,3%
|
8,98%
|
Marktkapitalisatie/omzet
|
2,83
x
|
2,79
x
|
4,79
x
|
1,35
x
|
1,21
x
|
1,58
x
|
1,55
x
|
1,54
x
|
Bedrijfswaarde/omzet
|
2,83
x
|
2,79
x
|
4,79
x
|
1,35
x
|
1,21
x
|
1,58
x
|
1,55
x
|
1,54
x
|
Bedrijfswaarde/EBITDA
|
6,87
x
|
4,75
x
|
-25,2
x
|
7,23
x
|
2,76
x
|
4,51
x
|
4,31
x
|
4,4
x
|
Bedrijfswaarde/FCF
|
14.442.826
x
|
21.418.312
x
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
0%
|
0%
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
5,22
x
|
1,34
x
|
0,75
x
|
0,86
x
|
-
|
1,19
x
|
1,06
x
|
0,96
x
|
Aantal aandelen (in duizenden)
|
889.785
|
879.968
|
879.968
|
879.968
|
879.968
|
879.968
|
-
|
-
|
Referentieprijs
2 |
19,77
|
7,432
|
4,970
|
5,741
|
8,626
|
11,81
|
11,81
|
11,81
|
Datum van publicatie
|
27/03/20
|
19/03/21
|
21/03/22
|
24/03/23
|
28/03/24
|
-
|
-
|
-
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Omzet
1 |
6.224
|
2.348
|
913,8
|
3.745
|
6.295
|
6.596
|
6.706
|
6.745
|
EBITDA
1 |
2.560
|
1.377
|
-173,5
|
698,4
|
2.745
|
2.304
|
2.412
|
2.361
|
Bedrijfsresultaat (EBIT)
1 |
2.474
|
1.255
|
-423,4
|
321,1
|
2.354
|
2.243
|
2.347
|
2.293
|
Operationele Marge
|
39,74%
|
53,43%
|
-46,33%
|
8,57%
|
37,4%
|
34%
|
35%
|
34%
|
Resultaat voor belastingen (EBT)
|
2.269
|
1.010
|
-667,2
|
-
|
2.127
|
-
|
-
|
-
|
Nettowinst (verlies)
|
1.919
|
839,5
|
-587,6
|
-
|
1.993
|
-
|
-
|
-
|
Nettomarge
|
30,83%
|
35,75%
|
-64,31%
|
-
|
31,66%
|
-
|
-
|
-
|
WPA
|
2,005
|
0,5300
|
-0,6700
|
0,0900
|
2,260
|
-
|
-
|
-
|
Free Cash Flow
|
1.218
|
305,3
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF-marge
|
19,57%
|
13%
|
-
|
-
|
-
|
-
|
-
|
-
|
Kasstroomconversie (ebitda)
|
47,59%
|
22,17%
|
-
|
-
|
-
|
-
|
-
|
-
|
Kasstroomconversie (nettowinst)
|
63,49%
|
36,37%
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per aandeel
2 |
0,6500
|
0,1000
|
-
|
-
|
-
|
1,000
|
0,9800
|
1,060
|
Datum van publicatie
|
27/03/20
|
19/03/21
|
21/03/22
|
24/03/23
|
28/03/24
|
-
|
-
|
-
|
Fiscaal tijdperk: december |
2022 S1
|
2022 S2
|
---|
Omzet
1 |
-
|
2.452
|
EBITDA
|
-
|
-
|
Bedrijfsresultaat (EBIT)
1 |
-
|
220,5
|
Operationele Marge
|
-
|
8,99%
|
Resultaat voor belastingen (EBT)
|
-
|
-
|
Nettowinst (verlies)
|
-32,8
|
-
|
Nettomarge
|
-
|
-
|
WPA
2 |
-0,0400
|
0,1300
|
Dividend per aandeel
|
-
|
-
|
Datum van publicatie
|
26/08/22
|
24/03/23
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Nettoschuldpositie
|
256
|
-
|
2.062
|
2.822
|
-
|
-
|
-
|
-
|
Nettokaspositie
|
-
|
1.509
|
-
|
-
|
-
|
-
|
-
|
-
|
Hefboom (schuld/ebitda)
|
0,1001
x
|
-
|
-11,89
x
|
4,04
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
1.218
|
305
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (netto-inkomsten/eigen vermogen)
|
48,9%
|
18,1%
|
-11%
|
1,31%
|
-
|
21,7%
|
20,8%
|
18,7%
|
ROA (netto-inkomsten/totale activa)
|
26,5%
|
8,62%
|
-5,85%
|
-
|
-
|
-
|
-
|
-
|
Totale activa
|
7.237
|
9.737
|
10.051
|
-
|
-
|
-
|
-
|
-
|
Nettoactief per aandeel
1 |
3,790
|
5,550
|
6,600
|
6,690
|
-
|
9,890
|
11,10
|
12,30
|
Cashflow per aandeel
|
1,540
|
1,180
|
-0,7500
|
-
|
-
|
-
|
-
|
-
|
Capex
|
576
|
994
|
356
|
-
|
-
|
-
|
-
|
-
|
Capex/omzet
|
9,26%
|
42,34%
|
38,99%
|
-
|
-
|
-
|
-
|
-
|
Datum van publicatie
|
27/03/20
|
19/03/21
|
21/03/22
|
24/03/23
|
28/03/24
|
-
|
-
|
-
|
Gemiddeld advies Accumuleren Laatste slotkoers
11,81
CNY Gemiddelde koersdoel
12,94
CNY Spread / Gemiddelde doel +9,57% Consensus |
Vaira. 1 jan.
|
Kapi.
|
---|
| +34,88% | 1,43 mld. | | +33,43% | 690 mld. | | +26,43% | 546 mld. | | -5,12% | 358 mld. | | +19,59% | 323 mld. | | +4,89% | 287 mld. | | +14,32% | 235 mld. | | +5,79% | 199 mld. | | -9,49% | 195 mld. | | +4,26% | 161 mld. |
Farmaceutische producten - Andere
|